TransMedics Acquires Organ Preservation Assets
Ticker: TMDX · Form: 8-K · Filed: Jul 29, 2024 · CIK: 1756262
| Field | Detail |
|---|---|
| Company | Transmedics Group, Inc. (TMDX) |
| Form Type | 8-K |
| Filed Date | Jul 29, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $14.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, assets, healthcare
TL;DR
TransMedics just bought organ preservation assets from Organogenesis, beefing up its transplant game.
AI Summary
TransMedics Group, Inc. announced the completion of its acquisition of certain assets related to the Organ Preservation business from Organogenesis Holdings Inc. on July 26, 2024. This strategic move is expected to enhance TransMedics' position in the organ transplant market.
Why It Matters
This acquisition allows TransMedics to expand its organ transplant solutions, potentially increasing its market share and revenue in a critical healthcare sector.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent integration risks and may not achieve expected synergies, impacting financial performance.
Key Players & Entities
- TransMedics Group, Inc. (company) — Registrant
- Organogenesis Holdings Inc. (company) — Seller of assets
- July 26, 2024 (date) — Date of acquisition completion
FAQ
What specific assets were acquired by TransMedics Group, Inc.?
The filing states that TransMedics Group, Inc. acquired certain assets related to the Organ Preservation business from Organogenesis Holdings Inc.
When did the acquisition of these assets become effective?
The acquisition of these assets was completed on July 26, 2024.
What is the primary business of TransMedics Group, Inc.?
TransMedics Group, Inc. is involved in the ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry, specifically focusing on organ transplant solutions.
What is the principal executive office address for TransMedics Group, Inc.?
The principal executive offices are located at 200 Minuteman Road, Andover, Massachusetts 01810.
What is the filing date of this Form 8-K?
This Form 8-K was filed on July 29, 2024.
Filing Stats: 638 words · 3 min read · ~2 pages · Grade level 14.4 · Accepted 2024-07-29 16:06:01
Key Financial Figures
- $14.0 million — C for a purchase price of approximately $14.0 million (together with the Prior Acquisitions,
Filing Documents
- d869479d8k.htm (8-K) — 24KB
- 0001193125-24-187550.txt ( ) — 139KB
- tmdx-20240726.xsd (EX-101.SCH) — 3KB
- tmdx-20240726_lab.xml (EX-101.LAB) — 17KB
- tmdx-20240726_pre.xml (EX-101.PRE) — 11KB
- d869479d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TRANSMEDICS GROUP, INC. Date: July 29, 2024 By: /s/ Stephen Gordon Name: Stephen Gordon Title: Chief Financial Officer and Treasurer